Clinical Trial

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-30; most recent amendment 2026-03-24.
Status change: Recruiting → Completed 2026-03-24
Status change: Not Yet Recruiting → Recruiting 2026-01-23
Trial Details
NCT Number NCT07223671
Lead Sponsor Bristol-Myers Squibb
Conditions Healthy Volunteers
Enrollment 30 participants
Start Date 2025-12-31
Primary Completion 2026-02-19 (estimated)
Study Completion 2026-03-19 (estimated)
Updated on ClinicalTrials.gov 2026-03-27